Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Carboplatin; Etoposide; Etoposide phosphate; Pemetrexed

Criteria

Inclusion Criteria:

• Clinical diagnosis of extensive stage small cell lung cancer (SCLC)

• Capable of self-care but may be unable to carry out any work activities.

• No prior anticancer therapy for SCLC

Exclusion Criteria:

• have previously participated in a study involving pemetrexed

• have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication